Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

被引：0
|
作者：
Yue Xi
Ting Li
Yun Xi
Xinyi Zeng
Ying Miao
Rui Guo
Min Zhang
Biao Li
机构：
[1] Ruijin Hospital,Department of Nuclear Medicine
[2] Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics
[3] Collaboration Innovation Center for Molecular Imaging of Precision Medicine,undefined
[4] Ruijin Center,undefined
[5] National Research Center for Translational Medicine at Shanghai,undefined
[6] Ruijin Hospital,undefined
[7] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Cancer Cell International | / 22卷
关键词：
Triple-negative breast cancer; hENT1; miR-143; Combination therapy; Gemcitabine resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Treatment of Metastatic Triple-Negative Breast Cancer
    Glendenning, Jennifer
    Irshad, Sheeba
    Tutt, Andrew
    CURRENT BREAST CANCER REPORTS, 2012, 4 (01) : 10 - 21
  • [22] Treatment of Metastatic Triple-Negative Breast Cancer
    Jennifer Glendenning
    Sheeba Irshad
    Andrew Tutt
    Current Breast Cancer Reports, 2012, 4 (1) : 10 - 21
  • [23] A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis
    Pawat Pattarawat
    Jessica T. Hunt
    Jacob Poloway
    Collin J. Archibald
    Hwa-Chain Robert Wang
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 415 - 425
  • [24] Clinical effectiveness and safety of gemcitabine plus capecitabine in the treatment of advanced triple-negative breast cancer
    Wang, Ya
    Zhu, Yulan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (05): : 1945 - 1952
  • [25] Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
    Bai, Xupeng
    Ni, Jie
    Beretov, Julia
    Graham, Peter
    Li, Yong
    JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (03): : 75 - 87
  • [26] miR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1
    Li, Yan
    Zhou, Yidong
    Mao, Feng
    Shen, Songjie
    Zhao, Bin
    Xu, Yali
    Lin, Yan
    Zhang, Xiaohui
    Cao, Xi
    Xu, Ying
    Chen, Chang
    Zhang, Jinqian
    Sun, Qiang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] Rational combination therapy against triple-negative breast cancer
    Al-Ejeh, F.
    Miranda, M.
    Simpson, P. T.
    Chenevix-Trench, G.
    Lakhani, S. R.
    Khanna, K. K.
    CANCER RESEARCH, 2012, 72
  • [28] Developing combination therapies with biologics in triple-negative breast cancer
    Gaudio, Gilda
    Martino, Enzo
    Pellizzari, Gloria
    Cavallone, Matteo
    Castellano, Grazia
    Omar, Abeid
    Katselashvili, Lika
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (10) : 1075 - 1094
  • [29] Development of novel combination therapy for triple-negative breast cancer
    Lee, H.
    Lee, K.
    Lee, J.
    Yoon, K.
    Mohammad, A. M.
    Park, H. S.
    Park, J. S.
    Lee, S. -T.
    Sohn, J.
    BREAST, 2019, 44 : S36 - S37
  • [30] miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells
    Li, Dengfeng
    Hu, Jiashu
    Song, Hongming
    Xu, Hui
    Wu, Chengyang
    Zhao, Bingkun
    Xie, Dan
    Wu, Tianqi
    Zhao, Junyong
    Fang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (05): : 2276 - 2285
12345